Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company will present a company presentation and participate in one-on-one.
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Conference Stockholm, Swe
As previously announced Mendus AB has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed issue. As a.
Mendus AB (publ) Interim Report January – June 2023 itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.